Medical Access and Reimbursement in Puerto Rico

Currently classified as a strictly controlled substance under Puerto Rico territorial scheduling (psilocybin/psilocyn appear in Puerto Rico's controlled‑substances listings) with no authorized medical use outside of approved clinical research. Possession, sale, and non‑research medical use are subject to territorial criminal and administrative sanctions consistent with federal scheduling. #

Currently classified as a Schedule I hallucinogenic amphetamine under U.S. federal law (3,4‑methylenedioxymethamphetamine is explicitly listed in 21 CFR 1308.11) and, by extension, is controlled in Puerto Rico consistent with federal and territorial law. There is no authorized clinical, routine medical reimbursement pathway for MDMA outside FDA approval (which would then permit regulated medical use) or formally authorized clinical trials. For practical purposes in Puerto Rico today, access is limited to properly authorized clinical research protocols. #

Esketamine (brand name SPRAVATO) is an FDA‑approved, Schedule III nasal spray for specific indications in adults and is available in Puerto Rico under the same federal regulatory framework as the U.S. mainland. SPRAVATO is approved for treatment‑resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior (indications per the FDA and Janssen updates) and is dispensed only through certified healthcare settings under a REMS program because of risks of sedation, dissociation, and potential for misuse. Coverage/reimbursement: clinical administration of SPRAVATO in Puerto Rico follows typical U.S. payer pathways — Medicare and many commercial plans may provide coverage subject to medical‑necessity criteria and prior authorization, but coverage policies vary by plan and by facility; manufacturer copay/assistance programs are also used by patients to offset out‑of‑pocket costs. Implementation nuances in Puerto Rico: providers and clinics must enroll in the SPRAVATO REMS and follow monitoring/administration requirements; facilities billing Puerto Rico Medicaid or Medicaid‑equivalent programs must follow local reimbursement rules and prior‑authorization processes, which can be more restrictive and variable than commercial insurance. Key references: SPRAVATO FDA regulatory history and Janssen communications documenting indications and REMS requirements. # #

Ketamine (racemic ketamine; Ketalar) is a Schedule III anesthetic agent with established FDA approval for anesthesia but is not FDA‑approved for any psychiatric disorder (i.e., depression/PTSD) and therefore its use for psychiatric indications in Puerto Rico is off‑label. Many private clinics in Puerto Rico and elsewhere offer IV/IM ketamine infusions or compounded ketamine formulations for depression, chronic pain, and other indications; these treatments are generally delivered in private, cash‑pay or out‑of‑network settings and are frequently not reimbursed by public or commercial payers because the indication is off‑label and compounded formulations are not FDA‑approved. The FDA has specifically warned about risks associated with compounded ketamine products and emphasized that ketamine is not FDA‑approved for psychiatric disorders; clinics offering infusion therapy typically require private payment and may assist with prior authorization for related services (monitoring, facility fees) on a case‑by‑case basis, but routine insurer reimbursement is uncommon. Regional/regulatory notes: providers must comply with controlled‑substance registration and local prescribing laws in Puerto Rico; clinics administering ketamine for psychiatric uses should maintain informed‑consent documentation and be aware of FDA guidance on compounded products. Representative references: FDA safety communication on compounded ketamine and contemporary reporting on payer practices for ketamine infusion therapy. # #

Currently classified as a Schedule I hallucinogen under federal regulation (dimethyltryptamine is explicitly listed in 21 C.F.R. §1308.11) and thus controlled in Puerto Rico with no authorized medical use outside properly authorized clinical research. Access for medical use is limited to investigational/IRB‑approved trials. #

Currently listed among Schedule I hallucinogenic tryptamines in the federal scheduling regulations (5‑methoxy‑N,N‑dimethyltryptamine is named in 21 C.F.R. §1308.11) and is therefore tightly controlled in Puerto Rico with no authorized routine medical use outside approved clinical trials. Access is effectively limited to authorized research contexts. #

Currently classified under Puerto Rico/federal controlled‑substance frameworks as a non‑authorized psychoactive (ibogaine is not an FDA‑approved therapeutic), and there is no authorized medical reimbursement pathway; its use is limited to approved clinical research where permitted. Outside clinical trials, it is effectively prohibited. #

Because ayahuasca contains DMT (a Schedule I substance), ayahuasca preparations are controlled under federal scheduling and Puerto Rico territorial law; there is no authorized medical or reimbursed access outside of sanctioned clinical research. Religious/ceremonial defenses exist in some U.S. contexts but do not create general medical reimbursement access in Puerto Rico. #

Mescaline is explicitly named in Puerto Rico's controlled‑substances listings and is also a Schedule I substance under federal regulation; there is no routine medical authorization or reimbursement for mescaline outside approved clinical trials. Traditional peyote uses by certain Indigenous groups in the U.S. mainland fall into narrow legal exceptions that do not translate into general medical reimbursement in Puerto Rico. # #

Compounds in the 2C family (e.g., 2C‑B and related phenethylamine hallucinogens) are covered under the federal Schedule I listings (21 C.F.R. §1308.11 includes 2C family members) and are therefore controlled in Puerto Rico; there is no authorized medical use or reimbursement other than within approved clinical research. Possession/distribution outside research is prohibited. #